{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Number of patients with Grade II-IV GVHD according to NMDP/CIBMTR GVHD severity scale. This scale measures the degree of GVHD involvement in the patient's skin (inflammatory skin disease), liver (bilirubin levels) and intestinal tract (amount of diarrhea) as well as the level of decline in a patient's activity and physical abilities.","groups":[{"description":"All patients that received Basiliximab 20 mg monoclonal therapy","id":"OG000","title":"Basiliximab 20 mg"}],"paramType":"NUMBER","populationDescription":"All patient that received study drug","timeFrame":"until 30 days after stem cell transplant","title":"Number of Patients With Acute Grade II-IV GVHD","type":"PRIMARY","unitOfMeasure":"participants"}